Zilebesiran

Details

Zilebesiran (Alnylam Pharmaceuticals) is an investigational small interfering RNA (siRNA) covalently linked to an N-acetylgalactosamine (GalNAc) ligand that binds the hepatic asialoglycoprotein receptor. After subcutaneous injection it is taken up by hepatocytes, where it silences angiotensinogen mRNA — the sole precursor of all angiotensin peptides — producing months-long suppression of the renin–angiotensin–aldosterone system from a dose given quarterly or twice yearly at most. It is not approved for clinical use; the evidence base is a phase 1 study in 107 patients with stage 1–2 hypertension (sources/zilebesiran-ht-nejm-2023, rating: high).

Key Facts

Mechanism

• Angiotensinogen is the only substrate from which angiotensin I, II and downstream peptides are generated, so silencing it acts upstream of ACE inhibition and ARB blockade. The intended advantage is that it avoids the compensatory angiotensin reactivation and aldosterone escape that blunt those drug classes. (sources/zilebesiran-ht-nejm-2023, rating: high)
• GalNAc conjugation restricts uptake to hepatocytes via the asialoglycoprotein receptor; preclinical data showed near-complete hepatic angiotensinogen knockdown without affecting renal angiotensinogen mRNA, which is the rationale for expecting less renal off-target effect than a systemic RAAS blocker.
• Like other GalNAc-siRNAs, the catalytic RISC mechanism means the duration of action is set by intrahepatic silencing rather than plasma drug levels — the basis for an infrequent dosing interval.

Phase 1 Evidence (NEJM 2023)

• Design: four-part phase 1 study at four UK sites. Part A single ascending dose (10–800 mg) randomised 2:1 against placebo, double-blind; Part B 800 mg under controlled low- and high-salt diets, double-blind; Part E 800 mg with add-on irbesartan, open-label. Part C was removed by amendment. (sources/zilebesiran-ht-nejm-2023, rating: high)
• Population: 107 patients, mean age 53.5 years (range 35–65), 62% men, 25% Black, mean 24-hour ambulatory systolic pressure 140.3 mmHg, after ≥2 weeks of antihypertensive washout. Diabetes, previous cardiovascular events and age >65 years were excluded.
• Target engagement: serum angiotensinogen fell with dose (r = −0.56 at week 8); doses ≥100 mg produced >90% suppression sustained from week 3 to week 12, and 800 mg maintained >90% through week 24.
• Blood pressure: doses ≥200 mg lowered 24-hour ambulatory systolic pressure by >10 mmHg and diastolic by >5 mmHg by week 8, day and night, sustained to week 24. At 800 mg the week-24 change was −22.5/−10.8 mmHg (n=8, six without add-on therapy). The systolic fall correlated with the degree of angiotensinogen reduction (r = 0.52).
• Salt interaction: low-salt diet alone −9.1/−2.4 mmHg; 800 mg plus low-salt −18.8/−8.4 mmHg; a high-salt diet (5.75 g/day) returned pressure to baseline.
• Add-on: irbesartan 300 mg in patients with persistent ambulatory systolic pressure ≥120 mmHg added a further −6.3/−3.0 mmHg.
• Safety: injection-site reactions were the only treatment-related event in more than two patients (5 patients, mild, transient). No deaths, no unplanned hospitalisations, no intervention for hypotension, hyperkalaemia or renal deterioration, and no clinically significant change in potassium, creatinine or eGFR. Transient low-titre antidrug antibodies in 2 of 80 (2%).

Dosing Concept

• A single subcutaneous dose suppresses angiotensinogen for at least 24 weeks, supporting a quarterly or twice-yearly schedule — a route to blood-pressure control that does not depend on daily adherence. (sources/zilebesiran-ht-nejm-2023, rating: high)
• The trade-off is that an injected depot cannot be titrated. The trial's high-salt reversal of the pressure effect is presented as a potential rescue mechanism rather than a tested one.

Contradictions / Open Questions

• No outcomes and no chronic-dosing data. The entire evidence base is a phase 1 study with no hypothesis testing, exploratory blood-pressure end points and 24-week follow-up; two phase 2 studies (KARDIA-1 and KARDIA-2) were under way at publication. Whether adherence-independent dosing translates into better blood-pressure control and fewer cardiovascular events than a daily tablet is unknown. (sources/zilebesiran-ht-nejm-2023, rating: high)
• The patients most likely to need it were excluded. Diabetes, prior cardiovascular events, age >65 years, CKD, heart failure and resistant hypertension were all excluded. Sustained angiotensinogen suppression in CKD or on a background ACE inhibitor/ARB is precisely where hyperkalaemia and acute kidney injury would be expected, and that risk is untested — the reassuring potassium and creatinine data come from a young, uncomplicated population on no background RAAS blocker after washout.
• Fixed dosing versus titratability. A once-quarterly injection removes non-adherence as a cause of uncontrolled pressure but also removes the ability to respond to intercurrent illness, volume depletion or hypotension within days. The claimed salt-based reversal is untested clinically, and no dose-adjustment algorithm exists.
• Efficacy is conditional on diet. A high-salt diet abolished the blood-pressure effect in Part B, which is both a mechanistic insight and a practical limitation: in patients with high sodium intake the drug may be substantially less effective.
• Reversibility cuts both ways. Slow offset is a safety feature if a patient becomes hypotensive, but it also means that an under-dosed or non-responding patient cannot be rescued quickly with a higher dose — the same property that makes inclisiran attractive for LDL-C (entities/Inclisiran) is less obviously attractive for a haemodynamic variable.
• Pregnancy and teratogenicity. Preclinical angiotensinogen siRNA did not cross the placenta or harm pups, but no human pregnancy data exist for this mechanism; conventional RAAS blockers are contraindicated in pregnancy. (sources/zilebesiran-ht-nejm-2023, rating: high)
• Liver specificity is inferred, not measured. Complete plasma and urinary RAAS metabolite data were not available to verify in humans the liver-restricted effect seen preclinically.

Connections

• Related to entities/Hypertension — novel mechanism for a condition where non-adherence is a principal cause of failure
• Related to concepts/Gene-Silencing-Therapy — GalNAc-siRNA modality applied to a haemodynamic rather than a genetic target
• Related to entities/Inclisiran — the closest approved analogue: same GalNAc-siRNA platform, same twice-yearly dosing logic, different target
• Related to entities/Vutrisiran and entities/Patisiran — siRNA therapeutics with established cardiovascular-adjacent outcomes data
• Related to concepts/Aldosterone-Synthase-Inhibitors — the other novel add-on mechanism being developed for uncontrolled hypertension; both act on the RAAS, one upstream of angiotensinogen, one on aldosterone synthesis
• Related to concepts/Renal-Denervation — catheter-based alternative for patients in whom adherence, not drug choice, is the limiting problem
• Related to concepts/Chronic-Kidney-Disease — untested population where RAAS suppression is most valuable and most hazardous

Sources

• sources/zilebesiran-ht-nejm-2023